Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Omeros Corporation is a clinical-stage biopharmaceutical company developing small-molecule and protein therapeutics targeting immune-related diseases, including complement-mediated disorders, cancers, and addiction. Its lead programs focus on complement system inhibitors, notably narsoplimab for thrombotic microangiopathies, and zaltenibart for rare blood and kidney diseases. The company owns extensive intellectual property and retains worldwide rights for its innovative biologics and small-molecule drug candidates.
This description was generated via AI from an annual report. Updated about 1 year ago.